Michelle Gilson
Stock Analyst at Morgan Stanley
(1.11)
# 3,660
Out of 4,945 analysts
31
Total ratings
32.14%
Success rate
-7.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Upgrades: Overweight | $10 → $20 | $4.44 | +350.45% | 4 | Jan 9, 2025 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $72.00 | -58.33% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $6.46 | +163.16% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $192.04 | +2.06% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $18.23 | +146.85% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $17.17 | +342.63% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $58.00 | +56.90% | 12 | Mar 1, 2021 |
Vir Biotechnology
Jan 9, 2025
Upgrades: Overweight
Price Target: $10 → $20
Current: $4.44
Upside: +350.45%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $72.00
Upside: -58.33%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $6.46
Upside: +163.16%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $192.04
Upside: +2.06%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $18.23
Upside: +146.85%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $17.17
Upside: +342.63%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $58.00
Upside: +56.90%